Fig. 2

Representative chromatograms for tedizolid in plasma and synovial fluid. (A) The patient in case 1 was treated with tedizolid once a day; her plasma samples were analyzed using fluorescence (thin line) and ultraviolet (solid line) detectors. (B) Tedizolid levels in samples of plasma (thin line) and synovial fluid (solid line) were determined using a fluorescence detector. The retention times of tedizolid and tedizolid phosphate derived from a dosage formulation were 15.3 and 12.9 min, respectively